← Eichor
Study identifier: NCT07596823 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hematological Indices and Sympathetic Block Response in Neuropathic Pain

Condition: Neuropathic Pain · Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4  ·  Sponsor: Ankara City Hospital Bilkent

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.

This description comes directly from the study's public registry record.

Talk to the study team

Ülkü Sabuncu, Assoc prof  ·  905337085212  ·  sabuncuulku@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ankara Bilkent City HospitalAnkara, Cankaya, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07596823